GlaxoSmithKline has licensed tumor-specific antigens from LICR
04/06/06 15:20 Filed in: LICR News
LICR and GlaxoSmithKline (GSK), the world's
second-largest pharmaceutical company, have announced
the signing of an agreement whereby GSK has licensed a
substantial portfolio of tumor-specific antigens from
LICR
... [ Read the press release ]
This licensing agreement follows a long-standing collaboration between both parties - specifically with the team led by Dr. Thierry Boon (Director, Brussels Branch) - on GSK's investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) in Non-Small Cell Lung Cancer (NSCLC).
GSK announced both the agreement and the results of a pivotal phase II trial of the MAGE-A3 ASCI at the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO) in June. LICR scientists and clinical investigators are expected to be involved in the continued design and interpretation of research results as the clinical development of the ASCI proceeds.
"We are very pleased to announce this agreement with the LICR the very same day the promising data from GSK's MAGE-A3 ASCI were presented. With the licensing of this impressive portfolio of cancer antigens, we endorse our collaboration with the Ludwig Institute and reaffirm our commitment to using our experience in immunology to develop innovative immunotherapies against a wide variety of oncology conditions."
Jean Stéphenne, President of GSK Biologicals.
... [ Read the press release ]
This licensing agreement follows a long-standing collaboration between both parties - specifically with the team led by Dr. Thierry Boon (Director, Brussels Branch) - on GSK's investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) in Non-Small Cell Lung Cancer (NSCLC).
GSK announced both the agreement and the results of a pivotal phase II trial of the MAGE-A3 ASCI at the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO) in June. LICR scientists and clinical investigators are expected to be involved in the continued design and interpretation of research results as the clinical development of the ASCI proceeds.
"We are very pleased to announce this agreement with the LICR the very same day the promising data from GSK's MAGE-A3 ASCI were presented. With the licensing of this impressive portfolio of cancer antigens, we endorse our collaboration with the Ludwig Institute and reaffirm our commitment to using our experience in immunology to develop innovative immunotherapies against a wide variety of oncology conditions."
Jean Stéphenne, President of GSK Biologicals.